Table 1.

Phase III randomised trials comparing chemoimmunotherapy with novel agents in the first-line of CLL. * mean; R, rituximab; G, obinutuzumab; CLB, chlorambucil; BR, bendamustin + rituximab; FCR, fludarabine + cyclophosphamide + rituximab; ibru, ibrutinib; acala, acalabrutinib; y, years; m, months; MRD, minimal residual disease; PFS, progression-free survival; OS, overall survival; NR, not reported.

Study	Patient Population	Study Design	Crossover	Median Age	MRD neg.	PFS	PFS Benefit	OS	OS Benefit	Reference
ECOG 1912	Younger/fit	R-ibru vs. FCR	No	57 vs. 57 *	8 vs. 59%	3y: 89 vs. 72%	Yes	3y: 99 vs. 92%	Yes	Shanafelt 2019
CLL14	Elderly/comorbid	G-venetoclax vs. G-CLB	No	72 vs. 71	76 vs. 35%	3y: 82 vs. 50%	Yes	3y: 88 vs. 87%	No	Fischer 2019; Al-Sawaf 2020
ILLUMINATE	Elderly/comorbid	G-ibru vs. G-CLB	Yes	70 vs. 72	30 vs. 20%	30m: 79 vs. 31%	Yes	30m: 86 vs. 85%	No	Moreno 2019
ELEVATE-TN	Elderly/comorbid	G-acala vs. acala vs. G-CLB	Yes	70 vs. 70 vs. 71	NR	2y: 93 vs. 87 vs. 47%	Yes	2y: 95 vs. 95 vs. 92%	No	Sharman 2020
ALLIANCE	Elderly/comorbid	R-ibru vs. ibru vs. BR	Yes	71 vs. 71 vs. 70	4 vs. 1 vs. 8%	2y: 88 vs. 87 vs. 74%	Yes	2y: 94 vs. 90 vs. 95%	No	Woyach 2018